Reactivation of Tuberculosis During Immunosuppressive Treatment in a Patient with a Positive QuantiFERON®-RD1 Test
- 8 July 2004
- journal article
- case report
- Published by Taylor & Francis in Scandinavian Journal of Infectious Diseases
- Vol. 36 (6-7) , 499-501
- https://doi.org/10.1080/00365540410015222
Abstract
A patient with polymyositis developed tuberculosis during immunosuppressive treatment. Tuberculin Skin Test and chest X-ray failed to demonstrate latent tuberculosis, whereas a blood sample that was tested with a modified QuantiFERON-TB-assay, using the recombinant ESAT-6 and CFP-10, was positive indicating that this patient was latently infected before immunosuppressive therapy. This case indicates the risk of progressing from latent to active tuberculosis given that the subject is RD1 responsive, and we believe that preventive anti-tuberculous treatment could have prevented this case of tuberculosis. We suggest that RD1 based tests are evaluated further in immunocompromised patients.Keywords
This publication has 3 references indexed in Scilit:
- Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical managementThe Lancet Infectious Diseases, 2003
- Immune Responses to the Mycobacterium tuberculosis -Specific Antigen ESAT-6 Signal Subclinical Infection among Contacts of Tuberculosis PatientsJournal of Clinical Microbiology, 2002
- Specific immune-based diagnosis of tuberculosisThe Lancet, 2000